Shares of Bone Biologics Co. (NASDAQ:BBLGW – Get Free Report) traded down 3.7% during mid-day trading on Monday . The stock traded as low as $9.97 and last traded at $10.39. 600 shares traded hands during mid-day trading, a decline of 66% from the average session volume of 1,786 shares. The stock had previously closed at $10.79.
Bone Biologics Stock Performance
The business has a 50-day simple moving average of $11.48 and a two-hundred day simple moving average of $14.53.
Bone Biologics Company Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
See Also
- Five stocks we like better than Bone Biologics
- How to Calculate Return on Investment (ROI)
- Eli Lilly Stock Soars on Trump Tariff Hopes and Pfizer Deal
- Roth IRA Calculator: Calculate Your Potential Returns
- 3 Exceptional Stocks to Build Long-Term Wealth
- Insider Trades May Not Tell You What You Think
- Insider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
